We are live on ! Find out more
RARX

Ra Pharmaceuticals, Inc. Common Stock
RARX

Delisted

RARX was delisted on the 1st of April, 2020.

Back to rankings

64 hedge funds and large institutions have $230M invested in Ra Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 14

2% less funds holding

Funds holding: 65 → 64 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

18% less capital invested

Capital invested by funds: $281M → $230M (-$50.7M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
64
Holders Change
-1
Holders Change %
-1.54%
% of All Funds
1.59%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
6
Increased
26
Reduced
14
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$6.56M
2
Citadel Advisors
Citadel Advisors
Florida
+$4.83M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$2.84M
4
GTC
Ghost Tree Capital
New York
+$2.27M
5
RPAM
Rhenman & Partners Asset Management
Sweden
+$1.81M

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$4.57M
2
NI
Numeric Investors
Massachusetts
-$2.48M
3
Fidelity International
Fidelity International
Bermuda
-$1.96M
4
NC
Nexthera Capital
New York
-$1.91M
5
UBS Group
UBS Group
Switzerland
-$986K

RARX Hedge Fund Activity: Q3 2017 in Review

64 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q3 2017, worth a combined $230M — down 18% from $281M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of RARX and 6 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 26 added.

The largest buyer was Millennium Management, adding an estimated $6.56M. The largest seller was Acuta Capital Partners, cutting an estimated $4.57M.

  • 64 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q3 2017, down from 65 in Q2 2017.
  • Funds reported $230M of Ra Pharmaceuticals, Inc. Common Stock stock for Q3 2017, down 18% quarter-over-quarter.
  • 6 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 7 closed out, a net change of -1 holder.
  • The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was Millennium Management, an estimated $6.56M added.
  • The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q3 2017 was Acuta Capital Partners, an estimated $4.57M sold.

Based on aggregated 13F filings for Q3 2017.